Clinical Trial: A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD

U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07086313) titled 'A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD' on July 17.

Brief Summary: The purpose of this study is to evaluate the efficacy and examine the safety of two doses of EB-1020 QD XR capsule administered once daily orally in pediatric ADHD patients.

Study Start Date: Aug., 2025

Study Type: INTERVENTIONAL

Condition: Attention-Deficit Hyperactivity Disorder(ADHD)

Intervention: DRUG: EB-1020 (Centanafadine) low dose

low dose, capsule, oral, once daily, for 6 weeks

DRUG: EB-1020 (Centanafadine) high dose

high dose, capsule, oral, once daily, for 6 weeks

DRUG: Placebo

Placebo, capsule, or...